We evaluated tumor specific MHC-I (tsMHC-I), tsMHC-II positive proportion of all the detected tumor cells in each patient, and the proportion of CD4 + and CD8 + T cell infiltration in each patient using multiplex immunohistochemistry (mIHC) (PanCK, HLA-A, HLA-DR, CD4, CD8, and DAPI) (Fig. 1B). This evidence concerns the gene CD4 and neoplasm.